Limax Biosciences is developing a next generation, stretchable hydrogel-based tissue adhesive to revolutionize treatments for injuries inside and outside the body. Existing hemostatic dressings and sealants have weak tissue adhesion that result in leaks, tissue rigidity, and cytotoxicity. Limax’s degradable, hydrogel-based material addresses these limitations through strong and rapid adhesion to wet tissue surfaces at 10-100x higher the strength of competitors. This patent-protected platform technology can be used in several indications throughout the body including soft tissue reinforcement and local drug delivery.
Limax Biosciences
Harvard Innovation Labs
Limax Biosciences
Treating internal and external injuries with a stretchable adhesive hydrogel.
Founders
Erika Bechtold
Harvard Medical School
Oktay Uzun
Harvard John A. Paulson School of Engineering and Applied Sciences
Edward Doherty
Harvard John A. Paulson School of Engineering and Applied Sciences
Dan Kent
Harvard Medical School
Kyle Wu
Harvard Medical School
Esther Koh
Harvard John A. Paulson School of Engineering and Applied Sciences
Benjamin Freedman
Harvard John A. Paulson School of Engineering and Applied Sciences
David Mooney
Harvard John A. Paulson School of Engineering and Applied Sciences
Emily Stoler
Harvard John A. Paulson School of Engineering and Applied Sciences
Brian Hibler
Non-Harvard Affiliate
Daniel Kent
About Limax Biosciences
Term
2023 Summer
School
Harvard Medical School
Programs
Blavatnik Harvard Life Lab Longwood
Connect
